Multiple myeloma (MM) remains incurable. Although early diagnosis improves outcomes, it has been unclear which populations to target for screening with serum electrophoresis, serum free light chains and urine electrophoresis. Here, we assessed the value of MM screening in a Fracture Liaison Service, ...
Researchers now think that multiple myeloma is difficult to treat because physicians have conventionally delayed therapy until end-organ damage, which in myeloma consists of bone destruction, anaemia and renal failure, is detected. It is time to start systematically screening for, and treating, early...
The screening imperative for multiple myeloma 来自 NCBI 喜欢 0 阅读量: 14 作者: SV Rajkumar 摘要: S. Vincent Rajkumar says there is enough evidence to begin testing, and treating, people at high risk of the disease much earlier. S. Vincent Rajkumar says there is enough evidence to begin ...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Updates in Version 1.2023 of the NCCN Guidelines for Multiple Myeloma from Version 5.2022 include: MYEL-1 • Initial Diagnostic Workup: 11th bullet modiied: Plasma cell luorescence in situ hybridization (FISH) panel on bone marrow [del(13), del(17p13), t(4;14), t(11;14), t(14...
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure. In approximately 30% of cases, MM is discovered through routine blood screening when patients are...
Since primary MM cell numbers can be limiting, compounds were rank-ordered for screening priority by likelihood of being clinically useful. The sensitivity of this MMDP was first profiled in a panel of 25 HMCLs (Supplemental Table 4) and then in a population of 113 primary myeloma patient ...
The commonly assumed target, RB1, showed complete LOF in 3.2% of patients, while DIS3 complete LOF was detected in 6.9% of patients; however, a striking number of additional genes were independently knocked out in myeloma (Fig. 1b). The following two contiguous gene regions with complete ...
Effect of TGFβ1, vactosertib and pomalidomide on the myeloma immunophenotype To determine the effect of vactosertib on the antigenicity of MM cells, we screened cell surface marker expression using a monoclonal antibody panel that detects 242 proteins. Screening allowed us to quantify the effect...
Impact of Integrating Distress Screening and Referral on Resource Utilization and Distress in Patients with Multiple Myeloma in an Industry Patient Assista... Buzaglo,Joanne,Kennedy,... - 《Psycho Oncology Journal of the Psychological Social & Behavioral Dimensions of Cancer》...